Effects of Lipoprotein-Associated Phospholipase A2 on Arginase/Nitric Oxide Pathway in Hemodialysis Patients

REFERENCES

• Bloembergen WE, Port FK, Mauger EA, Wolfe RA. A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol. 1995;6:177–183.
   PubMed Web of Science ®Google Scholar
• Stack AG, Bloembergen WE. Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: A cross-sectional study. J Am Soc Nephrol. 2001;12:1516–123.
   Google Scholar
• Vaziri ND. Causes of dysregulation of lipid metabolism in chronic renal failure. Semin Dial. 2009;22:644–651.
   Google Scholar
• Zoccali C. Cardiovascular risk in uraemic patients—is it fully explained by classical risk factors? Nephrol Dial Transplant. 2000;15:454–457.
   PubMed Web of Science ®Google Scholar
• Madjid M, Willerson JT. Inflammatory markers in coronary heart disease. Br Med Bull. 2011;100:23–38.
   PubMed Web of Science ®Google Scholar
• Bitla AR, Reddy PE, Manohar SM, Vishnubhotla SV, Pemmaraju Venkata Lakshmi Narasimha SR. Effect of a single hemodialysis session on inflammatory markers. Hemodial Int. 2010;14:411–417.
   PubMed Web of Science ®Google Scholar
• Errakonda PR, Paladugu R, Bitla AR, . Effect of a single hemodialysis session on endothelial dysfunction. J Nephrol. 2011;24:83–90.
   Google Scholar
• Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol. 2008;101:41–50.
   PubMed Web of Science ®Google Scholar
• Epps KC, Wilensky RL. Lp-PLA2—a novel risk factor for high-risk coronary and carotid artery disease. J Intern Med. 2011;269:94–106.
   Google Scholar
• Liu CF, Qin L, Ren JY, . Elevated plasma lipoprotein-associated phospholipase A2 activity is associated with plaque rupture in patients with coronary artery disease. Chin Med J (Engl). 2011;124:2469–2473.
   PubMed Web of Science ®Google Scholar
• McConnell JP, Hoefner DM. Lipoprotein-associated phospholipase A2. Clin Lab Med. 2006;26:679–697.
   PubMed Web of Science ®Google Scholar
• Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A(2) in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta. 2009;1791:327–338.
   PubMed Web of Science ®Google Scholar
• Bachetti T, Comini L, Francolini G, . Arginase pathway in human endothelial cells in pathophysiological conditions. J Mol Cell Cardiol. 2004;37:515–523.
   PubMed Web of Science ®Google Scholar
• Durante W, Johnson FK, Johnson RA. Arginase: A critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol. 2007;34:906–911.
   PubMed Web of Science ®Google Scholar
• Eleftheriadis T, Liakopoulos V, Antoniadi G, Stefanidis I, Galaktidou G. Arginase type I as a marker of coronary heart disease in hemodialysis patients. Int Urol Nephrol. 2011;43:187–194.
   Google Scholar
• Geyer JW, Dabich D. Rapid method for determination of arginase activity in tissue homogenates. Anal Biochem. 1971;39:412–417.
   PubMed Web of Science ®Google Scholar
• Cortas NK, Wakid NW. Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. Clin Chem. 1990;36:1440–1443.
   PubMed Web of Science ®Google Scholar
• Furberg CD, Nelson JJ, Solomon C, Cushman M, Jenny NS, Psaty BM. Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: The Cardiovascular Health Study. J Am Geriatr Soc. 2008;56:792–799.
   Google Scholar
• Milionis HJ, Elisaf MS, Karabina SA, Bairaktari E, Tselepis AD, Siamopoulos KC. Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures. Kidney Int. 1999;56:2276–2285.
   PubMed Web of Science ®Google Scholar
• Papavasiliou EC, Gouva C, Siamopoulos KC, Tselepis AD. PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin. Nephrol Dial Transplant. 2006;21:270–277.
   Google Scholar
• Liberopoulos EN, Papavasiliou E, Miltiadous GA, . Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis. Perit Dial Int. 2004;24:580–589.
   PubMed Web of Science ®Google Scholar
• Noto H, Chitkara P, Raskin P. The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes. J Diabetes Complications. 2006;20(6):343–348.
   Google Scholar
• Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol. 2006;26:1586–1593.
   PubMed Web of Science ®Google Scholar
• Holzer M, Birner-Gruenberger R, Stojakovic T, . Uremia alters HDL composition and function. J Am Soc Nephrol. 2011;22:1631–1641.
   PubMed Web of Science ®Google Scholar
• Korevaar JC, van Manen JG, Dekker FW, . Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol. 2004;15:2916–2922.
   PubMed Web of Science ®Google Scholar
• Lavi S, Herrmann J, Lavi R, McConnell JP, Lerman LO, Lerman A. Role of lipoprotein-associated phospholipase A2 in atherosclerosis. Curr Atheroscler Rep. 2008;10:230–235.
   PubMed Web of Science ®Google Scholar
• Santhanam L, Christianson DW, Nyhan D, Berkowitz DE. Arginase and vascular aging. J Appl Physiol. 2008;105:1632–1642.
   PubMed Web of Science ®Google Scholar
• Thacher TN, Gambillara V, Riche F, Silacci P, Stergiopulos N, da Silva RF. Regulation of arginase pathway in response to wall shear stress. Atherosclerosis. 2010;210:63–70.
   Google Scholar
• Morris SM Jr. Arginases and arginine deficiency syndromes. Curr Opin Clin Nutr Metab Care. 2012;15:64–70.
   PubMed Web of Science ®Google Scholar
• Ryoo S, Lemmon CA, Soucy KG, . Oxidized low-density lipoprotein-dependent endothelial arginase II activation contributes to impaired nitric oxide signaling. Circ Res. 2006;99:951–960.
   Web of Science ®Google Scholar
• Baylis C. Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Nat Clin Pract Nephrol. 2006;2:209–220.
   PubMedGoogle Scholar
• Yang Z, Ming XF. Endothelial arginase: A new target in atherosclerosis. Curr Hypertens Rep. 2006;8:54–59.
   Google Scholar
• Bellinghieri G, Santoro D, Mallamace A, Di Giorgio RM, De Luca G, Savica V. l-Arginine: A new opportunity in the management of clinical derangements in dialysis patients. J Ren Nutr. 2006;16:245–247.
   Google Scholar
• Luft FC. Arginase is an enzyme that nephrologists can love. J Hypertens. 2005;23:933–934.
   Google Scholar
• Sabbatini M, Pisani A, Uccello F, . Arginase inhibition slows the progression of renal failure in rats with renal ablation. Am J Physiol Renal Physiol. 2003;284:680–687.
   Google Scholar